|Videos|August 5, 2022
Future Directions in Metastatic Uveal Melanoma Treatment
Author(s)Omid Hamid, MD, Ryan Sullivan, MD
Omid Hamid, MD, and Ryan Sullivan, MD, discuss what they look forward to in the future of metastatic uveal melanoma treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
5